SE9103701D0
(sv)
*
|
1991-12-13 |
1991-12-13 |
Kabi Pharmacia Ab |
Apolipoprotein
|
SE9203753D0
(sv)
*
|
1992-12-11 |
1992-12-11 |
Kabi Pharmacia Ab |
Expression system for producing apolipoprotein ai-m
|
SE9500778D0
(sv)
*
|
1995-03-03 |
1995-03-03 |
Pharmacia Ab |
Process for producing a protein
|
FR2734568B1
(fr)
*
|
1995-05-22 |
1997-06-20 |
Rhone Poulenc Rorer Sa |
Nouveaux variants de l'apolipoproteine
|
US6258596B1
(en)
|
1995-05-22 |
2001-07-10 |
Aventis Pharmaceuticals Products Inc. |
Variants of apolipoprotein A-I
|
SE9603068D0
(sv)
*
|
1996-08-23 |
1996-08-23 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
SE9603304D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a compound
|
SE9603303D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
US6306433B1
(en)
|
1997-08-12 |
2001-10-23 |
Pharmacia Ab |
Method of preparing pharmaceutical compositions
|
US20020064820A1
(en)
*
|
2000-03-13 |
2002-05-30 |
Jean-Michel Dayer |
Apo-A-I regulation of T-cell signaling
|
EP1290013B1
(en)
*
|
2000-04-21 |
2006-03-08 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
BRPI0003386B8
(pt)
*
|
2000-08-08 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
JP4344136B2
(ja)
*
|
2000-11-10 |
2009-10-14 |
エフ・ホフマン−ラ・ロシュ・リミテッド |
アポリポタンパク質類似体
|
US7217785B2
(en)
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
NZ532217A
(en)
*
|
2001-09-28 |
2006-12-22 |
Esperion Therapeutics Inc |
Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
|
US20030229062A1
(en)
*
|
2001-12-07 |
2003-12-11 |
The Regents Of The University Of California |
Treatments for age-related macular degeneration (AMD)
|
AU2002360489A1
(en)
*
|
2001-12-07 |
2003-06-23 |
The Regents Of The University Of California |
Treatment for age-related macular degeneration
|
US7470659B2
(en)
*
|
2001-12-07 |
2008-12-30 |
The Regents Of The University Of California |
Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
|
US7223726B2
(en)
*
|
2002-01-14 |
2007-05-29 |
The Regents Of The University Of California |
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
EP1556413A4
(en)
*
|
2002-05-17 |
2009-07-08 |
Esperion Therapeutics Inc |
METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC REPERFUSION
|
EP1511508A4
(en)
|
2002-05-17 |
2009-07-08 |
Esperion Therapeutics Inc |
METHOD FOR TREATING DYSLIPIDARY INTERFERENCE
|
DE10324447A1
(de)
|
2003-05-28 |
2004-12-30 |
Scil Proteins Gmbh |
Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
|
PE20050438A1
(es)
*
|
2003-10-20 |
2005-06-14 |
Esperion Therapeutics Inc |
Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
|
WO2005051413A2
(en)
*
|
2003-11-26 |
2005-06-09 |
Novartis Ag |
Disease associated genes
|
AU2004299486B2
(en)
*
|
2003-12-15 |
2011-05-19 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
US8926958B2
(en)
|
2004-04-06 |
2015-01-06 |
Cedars-Sinai Medical Center |
Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
|
KR100560102B1
(ko)
*
|
2004-06-25 |
2006-03-13 |
한국생명공학연구원 |
프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
|
WO2012047930A2
(en)
*
|
2010-10-04 |
2012-04-12 |
The Regents Of The University Of California |
Compositions and methods for treatment of gynecologic cancers
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
CA2607483A1
(en)
|
2005-04-29 |
2006-11-09 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
WO2007000924A1
(ja)
*
|
2005-06-28 |
2007-01-04 |
Osaka University |
プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
|
KR100719389B1
(ko)
|
2005-10-18 |
2007-05-17 |
주식회사 녹십자 |
인간혈장으로부터 아포리포단백질 a-i을 분리 정제하는방법
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
WO2008021088A2
(en)
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
WO2008017906A1
(en)
*
|
2006-08-10 |
2008-02-14 |
Plantechno S.R.L. |
In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins
|
US8541236B2
(en)
*
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
US9422363B2
(en)
|
2007-08-28 |
2016-08-23 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
WO2009050266A2
(en)
*
|
2007-10-19 |
2009-04-23 |
Pronota N.V. |
Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
|
BRPI0818881A2
(pt)
|
2007-10-23 |
2015-05-05 |
Cleveland Clinic Foundation |
Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo
|
US8241861B1
(en)
|
2008-07-08 |
2012-08-14 |
Insilicos, Llc |
Methods and compositions for diagnosis or prognosis of cardiovascular disease
|
EP2355851B1
(en)
|
2008-11-10 |
2018-04-04 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
EP2391343B1
(en)
|
2009-01-29 |
2017-03-01 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
US8883202B2
(en)
|
2009-05-05 |
2014-11-11 |
Tekmira Pharmaceuticals Corporation |
Lipid compositions
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
EP2810643A3
(en)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
|
WO2011044545A2
(en)
|
2009-10-09 |
2011-04-14 |
Sigalov Alexander B |
Methods and compositions for targeted imaging
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
AU2010332932B2
(en)
*
|
2009-12-14 |
2013-01-17 |
Navigo Proteins Gmbh |
Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
|
WO2011075656A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011143362A1
(en)
|
2010-05-11 |
2011-11-17 |
Esperion Therapeutics, Inc. |
Dimeric oxidation-resistant apolipoprotein a1 variants
|
ES2634087T3
(es)
|
2010-06-03 |
2017-09-26 |
Alnylam Pharmaceuticals, Inc. |
Lípidos biodegradables para la administración de agentes activos
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130142760A1
(en)
|
2010-08-18 |
2013-06-06 |
Cedars-Sinai Medical Center |
Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
EP2663548B1
(en)
|
2011-01-11 |
2017-04-05 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
HUE041797T2
(hu)
|
2011-02-07 |
2019-05-28 |
Cerenis Therapeutics Holding Sa |
Lipoprotein-komplexek és elõállításuk és alkalmazásuk
|
CA2837804C
(en)
|
2011-06-15 |
2018-03-20 |
Scil Proteins Gmbh |
Dimeric binding proteins based on modified ubiquitins
|
RU2014108240A
(ru)
|
2011-08-25 |
2015-09-27 |
Ф. Хоффманн-Ля Рош Аг |
Укороченный тетранектин-аполипопротеин а-i гибридный белок, содержащая его липидная частица и их применения
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
WO2014011908A1
(en)
|
2012-07-11 |
2014-01-16 |
Esperion Therapeutics, Inc. |
Apolipoprotein mixtures
|
EP2853259A1
(en)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Reconstituted high density lipoproteins composition and uses thereof
|
SG11201609084QA
(en)
|
2014-05-02 |
2016-11-29 |
Cerenis Therapeutics Holding Sa |
Hdl therapy markers
|
CN107074923B
(zh)
|
2014-07-31 |
2021-08-03 |
Uab研究基金会 |
Apoe模拟肽及对清除血浆胆固醇的较高效力
|
US10858405B2
(en)
|
2015-02-06 |
2020-12-08 |
Navigo Proteins Gmbh |
EGFR binding proteins
|
US10808042B2
(en)
|
2015-07-16 |
2020-10-20 |
Navigo Proteins Gmbh |
Immunoglobulin-binding proteins and their use in affinity purification
|
US10584152B2
(en)
|
2015-07-20 |
2020-03-10 |
Navigo Proteins Gmbh |
Binding proteins based on di-ubiquitin muteins and methods for generation
|
WO2017191252A1
(en)
|
2016-05-04 |
2017-11-09 |
Navigo Proteins Gmbh |
Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
|
CA3030208A1
(en)
|
2016-08-11 |
2018-02-15 |
Navigo Proteins Gmbh |
Novel alkaline stable immunoglobulin binding proteins
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
CARGOMÈRES
|
US20190046608A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding Sa |
Apomers
|
EP3706804B1
(en)
|
2017-11-07 |
2022-02-23 |
Navigo Proteins GmbH |
Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
|
WO2021209823A1
(en)
|
2020-04-16 |
2021-10-21 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein- based complexes
|
AU2021354095A1
(en)
|
2020-10-01 |
2023-06-08 |
Abionyx Pharma Sa |
Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
|
JP2024514154A
(ja)
|
2021-04-15 |
2024-03-28 |
アビオニクス ファーマ エスエー |
臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
|
WO2023194798A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
WO2023237935A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|
WO2023237927A2
(en)
|
2022-06-10 |
2023-12-14 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
|